فهرست مطالب
Middle East Journal of Digestive Diseases
Volume:8 Issue: 3, July 2016
- تاریخ انتشار: 1395/05/13
- تعداد عناوین: 8
-
-
Pages 169-17329th of May has been convened as the world Digestive Health Day (WDHD) by the World Gastroenterology Organization (WGO) since 2005. This event is an opportunity to raise public awareness on topics related to gastrointestinal tract disease and health. The theme of 2016 is diet and the gut. The traditional approach to diet in gastroenterology practice is to advice patients to avoid certain foods to control their symptoms and /or disease.Keywords: Diet, Gut, Food
-
Pages 174-200Liver fibrosis is a reversible response to hepatic insults, triggered by different chronic diseases most importantly viral hepatitis, alcoholic, and non-alcoholic fatty liver diseases. In the course of chronic liver diseases, hepatic fibrogenesis may develop, which is attributed to various types of cells, molecules, and pathways. Activated hepatic stellate cell (HSC), the primary source of extracellular matrix (ECM), is fundamental in pathophysiology of fibrogenesis, and thus is the most attractable target for reversing liver fibrosis. Although, liver biopsy has long been considered as the gold standard for diagnosis and staging of hepatic fibrosis, assessing progression and regression by biopsy is hampered by its limitations, especially invasiveness. As a result, we provide recent views on non-invasive approaches including serum biomarkers and radiological techniques.
Several studies have asserted that reversion of fibrosis is an attainable goal. There are two main approaches in clinical reversion of liver fibrosis; eliminating the underlying insult, and targeting the fibrosis process. Here we review recent concepts in the field of pathogenesis, diagnosis, and therapeutic targets of liver fibrosis.Keywords: Liver Cirrhosis, Fibrosis, Pathogenesis, Diagnosis, Therapeutics, Genetic Therapy -
Pages 201-210BackgroundStandard anti-Helicobacter pylori (H. pylori) treatment fails in the eradication of the organism in almost 10-35% of the patients and has different side effects. Recent studies have proposed that probiotic supplementations with or without prebiotic may improve the eradication rate and diminish the side effects, although it is still a controversial issue. We aimed to investigate the effect of probiotic with prebiotic supplementation on the eradication rate and side effects of anti H. pylori quadruple therapy.Methods76 patients with a positive biopsy specimen for H. pylori were enrolled. They were randomized to receive quadruple therapy of bismuth, clarithromycin, amoxicillin, and omeprazole for 14 days and also the synbiotic or the placebo. We asked them to answer study questionnaires at the beginning and during the treatment. Finally, urea breath test was done 8 weeks after the treatment.ResultsThe eradication rate was significantly better in the synbiotic group by intention-to-treat analysis (pConclusionIn this study, the synbiotic supplementation did not diminish the frequency of symptoms during H. pylori eradication treatment but could improve the eradication by augmenting the treatment tolerance and compliance.Keywords: Eradication, H. pylori, Probiotic, Prebiotic, Synbiotic, Quadruple therapy
-
Pages 211-222BackgroundHepatitis E virus (HEV) is one of common causes of viral hepatitis worldwide with higher prevalence in tropical and subtropical regions. Although epidemics of HEV have been reported from Iran, there are variable reports of this infection out of epidemics from different parts of Iran. This study aimed to determine the seroprevalence of HEV in Iran.MethodsIn this systematic review and meta-analysis we searched PubMed, Scopus, Science direct, Google Scholar, Scientific Information Databank (SID), IranMedex, and Magiran for all relevant studies published in either English or Persian languages, up to 2015. Pooled seroprevalence estimates with a DerSimonian-Laird random-effects model were calculated. Statistical heterogeneity among the included studies was evaluated by Cochrane Q statistic and I2.Results38 studies fulfilled the inclusion criteria compromising 18461 participants. The pooled seroprevalence rate of HEV in Iran was estimated about 10% (95% CI=0.09-0.12) with maximum and minimum of 46% (95 % CI=0.42-0.50), and 0.01% (95 % CI=0.000-0.002), respectively.ConclusionHEV is common in Iran although the prevalence is lower than some neighbor countries.Keywords: Hepatitis E Virus_Seroprevalence_Meta_analysis_Systematic review_Iran
-
Factors Associated with Outcome in Patients with Acute Upper Gastrointestinal Bleeding in a Tertiary Referral Center in Northern IranPages 223-227BackgroundUpper gastrointestinal bleeding (UGIB) is a major healthcare problem and is the most frequent gastrointestinal reason for admission to hospital. We aimed to investigate the prognosis of patients with UGIB referred to a referral hospital in northern Iran in 2013.MethodsAll patients with UGIB who admitted to Sayyad Shirazi Hospital, in Gorgan, northern Iran, in 2013 were enrolled. The patients demographic data as well as data about admission, diseases, drug history, and patients prognosis were collected by structured questionnaire using information in hospital files. The relationships between different factors with the proportion of mortality and recurrence were assessed using Chi-square test.ResultsIn total, 168 patients were enrolled of whom 109 (64.9%) were male. The mean (SD) age of the patients was 59.4 (18.2) years. Mortality and recurrence occurred in 23.2% and 34.5% of the subjects, respectively. We found significant relationships between older age and diagnosis of malignancy with mortality (p =0.03 and pConclusionWe found relatively high rates of mortality and recurrence among patients with UGIB. Our results suggested older age and diagnosis of malignancy as the most important indicators of mortality and recurrence in such patients. Considering these factors in clinical settings may result in better and more effective management of patients with UGIB.Keywords: Upper Gastrointestinal Bleeding, Mortality, Recurrence
-
Pages 228-233BackgroundReflux disease is a common gastrointestinal problem. The association between reflux disease and gastritis pattern is controversial.
AIM: To determine the association between reflux disease and gastritis pattern in patients with Helicobacter pylori (H. pylori) infection.Methods470 patients with dyspepsia and reflux disease were enrolled in this study. The inclusion criteria were willing to participate in the study, age over 40 years, and having the criteria of ROME III for at least 3 months. Patients with history of H. pylori eradication therapy during the 3 months before the study, a history of gastric surgery, and gastric cancer were excluded. All of the participants underwent upper endoscopy and two biopsy samples were taken from antrum, body, and fundal areas.ResultH. pylori infection rate was 367 (78.1%) with mean age of 59.8±11.4 years. Of them 241 patients (51.2%) were male. Reflux disease was detected in 273 (74.4%) patients. 216 (58.9%) and 101 (27.5%) patients had non-erosive reflux disease (NERD)and gastroesophageal reflux disease (GERD), respectively. Corpus predominant and antral predominant gastritis were seen in 72 (19.6%) and 129 (35.2%) patients, respectively. Antral gastritis was significantly associated with GERD (PConclusionAccording to these finding ,we could suggest that the pattern of gastritis could be associated with reflux disease and GERD.Keywords: Gastroesophageal Reflux, GERD, Gastritis, Esophagus -
Pages 234-240IntroductionDue to limitation of colonoscopy in assessing the entire bowel and patients intolerance in inflammatory bowel disease (IBD), in the current study, we aimed to prospectively compare the accuracy of 99mTc(V)-dimercaptosuccinic acid (DMSA) and fecal calprotectin with ileocolonoscopy as new methods for localizing inflammations.MethodsCurrent prospective study conducted between 2012 and 2014 on 30 patients with IBD attending Gastroenterology Clinic of Tehran University of Medical Sciences. Fecal calprotectin and disease activity were measured for all participants and all of them underwent 99mTc (V)-DMSA scintigraphy and colonoscopy. The accuracy of 99mTc (V)-DMSA scintigraphy and calprotectin in localizing bowel lesions were calculated.ResultsA total of 22 patients with ulcerative colitis (UC) and 8 patients with Crohns disease (CD) were evaluated in our study. Sensitivity, positive likelihood ratio (PLR), and positive predictive value (PPV) of scintigraphy and calprotectin over colonoscopy in localization of UC lesions were 86.36%, 0.86%, 100.00% and 90.91%, 0.91, and 100.00%, respectively. Meanwhile, it showed 66.67% sensitivity and 81.25% specificity with PLR=3.56, negative likelihood ratio (NLR)=0.41, PPV=84.21%, and negative predictive value (NPV)= 61.90% in localizing lesions in patients with CD. The calprotectin level had sensitivity, PLR, and PPV of 90.00%, 0.90, and 100.00% in detecting active disease over colonoscopy, respectively.ConclusionThe 99mTc (V)-DMSA scintigraphy would be an accurate method for detecting active inflammation in follow-up of patients with IBD and assessing response to treatment as a non-invasive and complementary method beside colonoscopy for more accurate diagnosis of CD or UC.Keywords: 99mTc (V), DMSA scintigraphy, Inflammatory bowel disease, Clinical findings, Colonoscopy
-
Pages 241-247BackgroundHelicobacter pylori (H. pylori) is one of the most common bacterial infections worldwide. We designed a study to compare the efficacy of 14-day hybrid regimen with 10-day concomitant therapy for H. pylori eradication in Iran.Methods252 patients with naïve H. pylori infection were randomly divided to receive either hybrid regimen (pantoprazole 40 mg, and amoxicillin 1 gr twice daily for 14 days, accompanied by clarithromycin 500 mg, and metronidazole 500 mg, twice daily just during the last 7 days) or concomitant regimen (pantoprazole 40 mg, amoxicillin 1 gr, clarithromycin 500 mg, and metronidazole 500 mg, all twice daily for 10 days). 8 weeks after therapy, 14C- urease breath test was performed to confirm eradication.ResultsAccording to intention to treat analysis, the eradication rates were 87.3% (95% CI: 81.493.1) and 80.9% (95% CI: 74-87.8) in hybrid and concomitant groups, respectively (p=0.38). Per-protocol eradication rates were 89.3% (95% CI: 83.8-94.7) and 83.1% (95% CI: 76.3-89.8), respectively (p =0.19). The rates of severe side effects were not statistically different between the two groups (4% vs. 8.7%).Conclusion14-day hybrid therapy can be considered as a nearly acceptable regimen with few severe side effects in Iran. However, it seems that the efficacy of this therapy is decreasing as the resistance rates to antibiotics are increasing. We suggest further studies to assess the efficacy of a more prolonged concomitant therapy for H. pylori eradication in Iran.Keywords: Helicobacter Pylori, Eradication, Hybrid regimen